Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.

Tarek N, Le Luduec JB, Gallagher MM, Zheng J, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC.

J Clin Invest. 2012 Sep;122(9):3260-70. doi: 10.1172/JCI62749. Epub 2012 Aug 6.

2.

B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.

Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.

Exp Hematol. 2010 Mar;38(3):213-21. doi: 10.1016/j.exphem.2009.12.007. Epub 2010 Jan 6.

PMID:
20056126
3.

Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.

Shibina A, Seidel D, Somanchi SS, Lee DA, Stermann A, Maurer BJ, Lode HN, Reynolds CP, Huebener N.

J Mol Med (Berl). 2013 Apr;91(4):459-72. doi: 10.1007/s00109-012-0958-0. Epub 2012 Sep 30.

PMID:
23052481
4.

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM.

Cancer Immunol Res. 2014 Sep;2(9):878-89. doi: 10.1158/2326-6066.CIR-13-0158. Epub 2014 Jun 23.

5.

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.

Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC.

Clin Cancer Res. 2013 Apr 15;19(8):2132-43. doi: 10.1158/1078-0432.CCR-12-1243. Epub 2013 Feb 1.

6.

KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.

Terszowski G, Klein C, Stern M.

J Immunol. 2014 Jun 15;192(12):5618-24. doi: 10.4049/jimmunol.1400288. Epub 2014 May 2.

7.

Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.

Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W.

Clin Cancer Res. 2012 Nov 15;18(22):6296-305. doi: 10.1158/1078-0432.CCR-12-0668. Epub 2012 Sep 26.

8.

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

Esser R, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS.

J Cell Mol Med. 2012 Mar;16(3):569-81. doi: 10.1111/j.1582-4934.2011.01343.x.

9.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS.

Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26.

10.

Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.

Kajitani K, Tanaka Y, Arihiro K, Kataoka T, Ohdan H.

Breast Cancer Res Treat. 2012 Jul;134(1):139-55. doi: 10.1007/s10549-011-1944-x. Epub 2012 Jan 20.

PMID:
22261932
11.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N.

Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24.

12.

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.

Seidel D, Shibina A, Siebert N, Wels WS, Reynolds CP, Huebener N, Lode HN.

Cancer Immunol Immunother. 2015 May;64(5):621-34. doi: 10.1007/s00262-015-1669-5. Epub 2015 Feb 25.

PMID:
25711293
14.

Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction.

Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, Zocchi MR, Poggi A.

Blood. 2002 Dec 1;100(12):4098-107. Epub 2002 Jul 18.

15.

Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Binyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM.

J Immunol. 2008 May 1;180(9):6392-401.

16.

Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products.

Itescu S, Artrip JH, Kwiatkowski PA, Wang SF, Minanov OP, Morgenthau AS, Michler RE.

Ann Transplant. 1997;2(1):14-20.

PMID:
9869836
17.

Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands.

Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC.

J Immunol. 2007 Nov 1;179(9):5977-89. Erratum in: J Immunol. 2007 Dec 15;179(12):8570.

18.

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN.

Mol Immunol. 2005 Jul;42(11):1311-9. Epub 2005 Apr 7.

PMID:
15950727
19.

Susceptibility of human melanoma cells to autologous natural killer (NK) cell killing: HLA-related effector mechanisms and role of unlicensed NK cells.

Carrega P, Pezzino G, Queirolo P, Bonaccorsi I, Falco M, Vita G, Pende D, Misefari A, Moretta A, Mingari MC, Moretta L, Ferlazzo G.

PLoS One. 2009 Dec 4;4(12):e8132. doi: 10.1371/journal.pone.0008132.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk